Search - tctmd.com

Displaying 281 - 300 of 39119

Sort: Relevancy | Date

Presentation THT 2026

Smart Adaptive LVAD to Tailor its Operation to Physiological State during Day

Presenter: Jonathan Grinstein

March 02, 2026

Presentation THT 2026

Implications for IABP Use in HF Shock With the New Allocation System

Presenter: Ulrich P. Jorde

March 02, 2026

Presentation THT 2026

YES: TEER is Totally Appropriate for Patients With Moderate MR if HF

Presenter: Stefan Anker

March 02, 2026

Presentation THT 2026

Self-Management of Pressures to Reduce HF Hospitalizations

Presenter: Anique Ducharme

March 02, 2026

Presentation THT 2026

Development and Validation of a Model to Predict Risk of Dialysis Following Ventricular Assist Device Placement

Presenter: Wendy McCallum

March 02, 2026

Presentation THT 2026

Does the Future Rest on Multiparametric Devices?

Presenter: Gerin R. Stevens

March 02, 2026

Presentation THT 2026

Left Ventricular Assist Devices And Cachexia: Improved Outcomes With Nutritional Consult Intervention

Presenter: Manthan Patel

March 02, 2026

Presentation THT 2026

Implications for IABP Use in Shock: Lessons Learned From the Cardiogenic Shock Registry

Presenter: Arthur Reshad Garan

March 02, 2026

Presentation THT 2026

Wearable Devices for Outpatient Monitoring — Where are we Today?

Presenter: Gabriel Sayer

March 02, 2026

Presentation THT 2026

Comparing the Strategy of LVAD versus Heart Transplantation Listing by Age in National US Data: Informing Patient Centered Decision Making

Presenter: Thomas Cascino

March 02, 2026

Presentation THT 2026

Antagonist: Deep Phenotyping and Phenomapping Has Been and Will Continue to Be A Mirage in Understanding the Mechanisms and Tailoring Treatment for HFpEF.

Presenter: Milton Packer

March 02, 2026

Presentation THT 2026

Implantable Pressure-Base Remote Monitoring Devices: What are the Differences?

Presenter: Liviu Klein

March 02, 2026

Presentation THT 2026

Clinical Viewpoint: Fallout from the IABP Shock II and Alt-Shock Studies

Presenter: Joyce Wanglee Wald

March 02, 2026

Presentation THT 2026

Protagonist: HFpEF is Highly Heterogeneous, Requiring a Multimodal Precision Medicine Approach for True Progress.

Presenter: Sanjiv J. Shah

March 02, 2026

Presentation THT 2026

Remote Monitoring to Optimize GDMT Beyond Diuretics

Presenter: Lynne Warner Stevenson

March 02, 2026

Presentation THT 2026

Perioperative Management and Outcomes of Heparin-Induced Thrombocytopenia in Patients Undergoing HeartMate 3 Left Ventricular Assist Device Implantation: A Case Series

Presenter: Vaidehi Mendpara

March 02, 2026

Presentation THT 2026

Introduction: The Hemodynamic Basis of the Use of IABP in AMI- and HF-Shock

Presenter: Francesco Castagna

March 02, 2026

Presentation THT 2026

HeartCon: Pioneering VAD Development in China

Presenter: Xiaocheng Liu

March 02, 2026

Presentation THT 2026

Predicted vs. Observed 3-Year Mortality in the ALT FLOW Early Feasibility Study Cohort

Presenter: Javed Butler

March 02, 2026

Presentation THT 2026

Disentangling The Central, Peripheral And Hematological Mechanisms Of Benefit Of Sotatercept On Exercise Performance In Pulmonary Arterial Hypertension

Presenter: Yogesh Reddy

March 02, 2026

Advertisement

Smart Adaptive LVAD to Tailor its Operation to Physiological State during Day

Implications for IABP Use in HF Shock With the New Allocation System

YES: TEER is Totally Appropriate for Patients With Moderate MR if HF

Self-Management of Pressures to Reduce HF Hospitalizations

Development and Validation of a Model to Predict Risk of Dialysis Following Ventricular Assist Device Placement

Does the Future Rest on Multiparametric Devices?

Left Ventricular Assist Devices And Cachexia: Improved Outcomes With Nutritional Consult Intervention

Implications for IABP Use in Shock: Lessons Learned From the Cardiogenic Shock Registry

Wearable Devices for Outpatient Monitoring — Where are we Today?

Comparing the Strategy of LVAD versus Heart Transplantation Listing by Age in National US Data: Informing Patient Centered Decision Making

Antagonist: Deep Phenotyping and Phenomapping Has Been and Will Continue to Be A Mirage in Understanding the Mechanisms and Tailoring Treatment for HFpEF.

Implantable Pressure-Base Remote Monitoring Devices: What are the Differences?

Clinical Viewpoint: Fallout from the IABP Shock II and Alt-Shock Studies

Protagonist: HFpEF is Highly Heterogeneous, Requiring a Multimodal Precision Medicine Approach for True Progress.

Remote Monitoring to Optimize GDMT Beyond Diuretics

Perioperative Management and Outcomes of Heparin-Induced Thrombocytopenia in Patients Undergoing HeartMate 3 Left Ventricular Assist Device Implantation: A Case Series

Introduction: The Hemodynamic Basis of the Use of IABP in AMI- and HF-Shock

HeartCon: Pioneering VAD Development in China

Predicted vs. Observed 3-Year Mortality in the ALT FLOW Early Feasibility Study Cohort

Disentangling The Central, Peripheral And Hematological Mechanisms Of Benefit Of Sotatercept On Exercise Performance In Pulmonary Arterial Hypertension

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content